Rufinamide add-on therapy for refractory epilepsy.
CONCLUSIONS: In people with drug-resistant focal epilepsy, rufinamide when used as an add-on treatment was effective in reducing seizure frequency. However, the trials reviewed were of relatively short duration and provided no evidence for the long-term use of rufinamide. In the short term, rufinamide as an add-on was associated with several adverse events. This review focused on the use of rufinamide in drug-resistant focal epilepsy and the results cannot be generalised to add-on treatment for generalised epilepsies. Likewise, no inference can be made about the effects of rufinamide when used as monotherapy.
PMID: 29691835 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Panebianco M, Prabhakar H, Marson AG Tags: Cochrane Database Syst Rev Source Type: research
More News: Brain | Child Development | Children | Clinical Trials | Databases & Libraries | Epilepsy | General Medicine | Headache | Inovelon | Migraine | Neurology | Rufinamide | Study